prikaz prve stranice dokumenta An Overview on Anticancer Activities of the Viscum Album Extract Isorel®
Access restricted to students and staff of home institution
Scientific paper - Original scientific paper
An Overview on Anticancer Activities of the Viscum Album Extract Isorel®
Cancer Biotherapy and Radiopharmaceuticals, 16 (2001), 1; 55-62. https://doi.org/10.1089/108497801750096041
Zarkovic, Neven; Vukovic, Tea; Loncaric, Iva; Miletic, Martina; Zarkovic, Kamelija; Borovic, Suzana; Cipak, Ana; Sabolovic, Senka; Konitzer, Martin; Mang, Susanne

Citations:
,
Cite this document

Zarkovic, N., Vukovic, T., Loncaric, I., Miletic, M., Zarkovic, K., Borovic, S. ... Mang, S. (2001). An Overview on Anticancer Activities of the Viscum Album Extract Isorel®. Cancer Biotherapy and Radiopharmaceuticals, 16. (1), 55-62. doi: 10.1089/108497801750096041

Zarkovic, Neven, et al. "An Overview on Anticancer Activities of the Viscum Album Extract Isorel®." Cancer Biotherapy and Radiopharmaceuticals, vol. 16, no. 1, 2001, pp. 55-62. https://doi.org/10.1089/108497801750096041

Zarkovic, Neven, Tea Vukovic, Iva Loncaric, Martina Miletic, Kamelija Zarkovic, Suzana Borovic, Ana Cipak, Senka Sabolovic, Martin Konitzer and Susanne Mang. "An Overview on Anticancer Activities of the Viscum Album Extract Isorel®." Cancer Biotherapy and Radiopharmaceuticals 16, no. 1 (2001): 55-62. https://doi.org/10.1089/108497801750096041

Zarkovic, N., et al. (2001) 'An Overview on Anticancer Activities of the Viscum Album Extract Isorel®', Cancer Biotherapy and Radiopharmaceuticals, 16(1), pp. 55-62. doi: 10.1089/108497801750096041

Zarkovic N, Vukovic T, Loncaric I, Miletic M, Zarkovic K, Borovic S, and sur.. An Overview on Anticancer Activities of the Viscum Album Extract Isorel®. Cancer Biotherapy and Radiopharmaceuticals [Internet]. 2001 February [cited 2025 April 01];16(1):55-62. doi: 10.1089/108497801750096041

N. Zarkovic, et al., "An Overview on Anticancer Activities of the Viscum Album Extract Isorel®", Cancer Biotherapy and Radiopharmaceuticals, vol. 16, no. 1, pp. 55-62, February 2001. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:220:045339. [Accessed: 01 April 2025]

Please login to the repository to save this object to your list.
Metadata
Title (english)An Overview on Anticancer Activities of the Viscum Album Extract Isorel®
AuthorNeven Zarkovic
AuthorTea Vukovic
AuthorIva Loncaric
AuthorMartina Miletic
AuthorKamelija Zarkovic
AuthorSuzana Borovic
AuthorAna Cipak
AuthorSenka Sabolovic
AuthorMartin Konitzer
AuthorSusanne Mang
Author's institution(Sestre milosrdnice University Hospital Center)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
The activity principle of the mistletoe (Viscum album L.) phytotherapeutics could be considered as combined cytotoxic and "biological response modifying" activities (increasing host defense against cancer) that result from the activities of the plant lectins and the other biologically relevant substances. We found before that the aqueous extract Isorel, produced by Novipharm GmbH (Pörtschach, Austria) from the entire plant (planta tota) of fresh mistletoe under standardized conditions with... More bioassay validated batch consistency, can be valuable in experimental adjuvant cancer therapy increasing efficiency of cyclophosphamide chemotherapy. In current study we found that Isorel increases the reactivity of the tumor-bearing mice lymphocytes to the mitogens (ConA and LPS) in vitro, thus indicating its immune stimulating effects for the cancer-immunosuppressed lymphocytes. Moreover, Isorel inhibited the incorporation of 3H-labelled amino acids (protein synthesis) in various malignant cell lines. For the growth inhibition mostly higher MW components were responsible, although even less than 500 Da components were also active. We further analyzed the effects of drug application in vicinity of tumor (murine mammary carcinoma) and compared it with systemic effects. The animals carried mammary carcinoma in both hind limbs and were also injected with tumor cells i.v. to develop artificial lung metastases. Isorel was applied only at the right side (in the limb distal from the tumor) and caused persistent and almost complete inhibition of the tumor growth for 2/7 animals. Anticancer effects were less pronounced on the contralateral side tumors, although tumor growth rate was transiently reduced for some mice. Histology revealed that Isorel treatment, both at the side of tumor and systemically, increased the incidence of apoptosis and necrosis in the tumors, while reduction of mitosis was noticed only for the tumors in vicinity of the tumor exposed to Isorel. Finally, animals treated with Isorel had, on the average, three times less lung metastases than the controls. Thus, we conclude that both local and systemic effects of the application of Isorel could be of benefit for the tumor-bearing organism resulting in immunomodulation combined with tumor growth inhibition and reduction of metastases. According to the in vitro results, antitumorous effects could be the result not only of the mistletoe lectins and the other high MW factors, but also of the very low MW (< 500 Da) substances that deserve further analyses. Less
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleCancer Biotherapy and Radiopharmaceuticals
Numberingvol. 16, no. 1, pp. 55-62
p-ISSN1084-9785
e-ISSN1557-8852
DOIhttps://doi.org/10.1089/108497801750096041
URN:NBNurn:nbn:hr:220:045339
Publication2001-02
Document URLhttp://www.liebertpub.com/doi/10.1089/108497801750096041
Type of resourceText
Access conditionsInstitutional access
Terms of useLicence In copyright icon
Created on2024-10-18 09:50:00
accessibility

closeAccessibilityrefresh

If you wish to permanently save changes, click on Save, if not - your settings will be reset when you restart the browser.